| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2000;102:1611.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Division of Cardiology, Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, Calif.
Correspondence to Bojan Cercek, Division of Cardiology, Cedars-Sinai Medical Center, Room 5314, 8700 Beverly Blvd, PO Box 48750, Los Angeles, CA 90048-1865. E-mail cercek{at}cshs.org
BackgroundIn patients with acute myocardial infarction (AMI) undergoing thrombolytic therapy, an elevated troponin level on admission is associated with a lower reperfusion rate and a complicated clinical course. Whether an elevated troponin level on admission similarly predicts an adverse outcome in patients undergoing primary angioplasty is currently unknown and was investigated in the present study.
Methods and ResultsCardiac troponin I (cTnI) was determined on
admission in 110 consecutive patients with AMI associated with
ST-segment elevation or left bundle branch block who underwent primary
angioplasty. Fifty-four patients (49%) had an elevated cTnI (
0.4
ng/mL) on admission. In patients with elevated cTnI, primary
angioplasty was less likely to achieve TIMI 3 flow (as classified by
the Thrombolysis in Myocardial Infarction trial) in
univariate (76% versus 96%, P=0.03) or in
multivariate (odds ratio 0.1, 95% CI 0.02 to 0.54)
analysis. Patients with elevated cTnI were more likely to
develop congestive heart failure (23% versus 9%,
P<0.05) and death, heart failure, or shock (30% versus
9%, P=0.006). Elevated cTnI remained a significant
predictor of the composite end point after controlling for other
clinical data that were available early in the course, including time
to presentation and angiographic results (relative risk
5.2, 95% CI 1.03 to 26.3). During a follow-up of 426±50 days,
elevated admission cTnI was a predictor of cardiac mortality (11%
versus 0%, P=0.012), adverse cardiac events (cardiac
mortality or nonfatal reinfarction; 19% versus 5.4%,
P=0.04), and adverse cardiac events plus target vessel
revascularization (32% versus 14%,
P=0.054).
ConclusionsIn patients with ST-segment elevation AMI, an elevated cTnI on admission is associated with an increased risk of primary angioplasty failure and a more complicated clinical course.
Key Words: angioplasty myocardial infarction reperfusion proteins
This article has been cited by other articles:
![]() |
P. O Collinson, G. H Gaynor, and D. C Gaze Cardiac troponin I measurement using the ACS:180 to predict four-year cardiac event rate Ann Clin Biochem, March 1, 2008; 45(2): 184 - 188. [Abstract] [Full Text] [PDF] |
||||
![]() |
S G Foussas, M N Zairis, S S Makrygiannis, S J Manousakis, F A Anastassiadis, C S Apostolatos, N G Patsourakos, M P Glyptis, J K Papadopoulos, D C Xenos, et al. The significance of circulating levels of both cardiac troponin I and high-sensitivity C reactive protein for the prediction of intravenous thrombolysis outcome in patients with ST-segment elevation myocardial infarction Heart, August 1, 2007; 93(8): 952 - 956. [Abstract] [Full Text] [PDF] |
||||
![]() |
NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, and R. H. Christenson National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes Circulation, April 3, 2007; 115(13): e356 - e375. [Full Text] [PDF] |
||||
![]() |
NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, R. H. Christenson, NACB COMMITTEE MEMBERS, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes Clin. Chem., April 1, 2007; 53(4): 552 - 574. [Full Text] [PDF] |
||||
![]() |
A. S. Jaffe, L. Babuin, and F. S. Apple Biomarkers in Acute Cardiac Disease: The Present and the Future J. Am. Coll. Cardiol., July 4, 2006; 48(1): 1 - 11. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Thielmann, P. Massoudy, M. Neuhauser, K. Tsagakis, G. Marggraf, M. Kamler, K. Mann, R. Erbel, and H. Jakob Prognostic Value of Preoperative Cardiac Troponin I in Patients Undergoing Emergency Coronary Artery Bypass Surgery With Non-ST-Elevation or ST-Elevation Acute Coronary Syndromes Circulation, July 4, 2006; 114(1_suppl): I-448 - I-453. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. L. Miller, K. N. Garratt, M. F. Burritt, R. J. Lennon, G. S. Reeder, and A. S. Jaffe Baseline troponin level: key to understanding the importance of post-PCI troponin elevations Eur. Heart J., May 1, 2006; 27(9): 1061 - 1069. [Abstract] [Full Text] [PDF] |
||||
![]() |
Part 5: Acute Coronary Syndromes Circulation, November 29, 2005; 112(22_suppl): III-55 - III-72. [Full Text] [PDF] |
||||
![]() |
M. Thielmann, P. Massoudy, M. Neuhauser, S. Knipp, M. Kamler, J. Piotrowski, K. Mann, and H. Jakob Prognostic Value of Preoperative Cardiac Troponin I in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery Chest, November 1, 2005; 128(5): 3526 - 3536. [Abstract] [Full Text] [PDF] |
||||
![]() |
T Nageh, R A Sherwood, B M Harris, and M R Thomas Prognostic role of cardiac troponin I after percutaneous coronary intervention in stable coronary disease Heart, September 1, 2005; 91(9): 1181 - 1185. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ishii, Y. Ozaki, J. Lu, F. Kitagawa, T. Kuno, T. Nakano, Y. Nakamura, H. Naruse, Y. Mori, S. Matsui, et al. Prognostic Value of Serum Concentration of Heart-Type Fatty Acid-Binding Protein Relative to Cardiac Troponin T on Admission in the Early Hours of Acute Coronary Syndrome Clin. Chem., August 1, 2005; 51(8): 1397 - 1404. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Thielmann, P. Massoudy, M. Neuhauser, S. Knipp, M. Kamler, G. Marggraf, J. Piotrowski, and H. Jakob Risk stratification with cardiac troponin I in patients undergoing elective coronary artery bypass surgery Eur. J. Cardiothorac. Surg., May 1, 2005; 27(5): 861 - 869. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Leoncini, F. Bellandi, R. Sciagra, M. Maioli, A. Toso, A. Coppola, S. Sestini, A. Mennuti, R. P. Dabizzi, and A. Pupi Gated SPECT Evaluation of the Relationship Between Admission Troponin I, Myocardial Salvage, and Functional Recovery in Acute Myocardial Infarction Treated by Abciximab and Early Primary Angioplasty J. Nucl. Med., May 1, 2004; 45(5): 739 - 744. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Bjorklund, B. Lindahl, P. Johanson, T. Jernberg, A.-M. Svensson, P. Venge, L. Wallentin, M. Dellborg, and the ASSENT-2 and ASSENT-PLUS study groups Admission Troponin T and measurement of ST-segment resolution at 60 min improve early risk stratification in ST-elevation myocardial infarction Eur. Heart J., January 2, 2004; 25(2): 113 - 120. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Panteghini Acute Coronary Syndrome: Biochemical Strategies in the Troponin Era Chest, October 1, 2002; 122(4): 1428 - 1435. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. A. Khan, N. Wattanasuwan, N. J. Mehta, A. Tun, N. Singh, H. K. Singh, B. C. Vasavada, and T. J. Sacchi Prognostic value of serum cardiac troponin I in ambulatory patients with chronic renal failure undergoing long-term hemodialysis: A two-year outcome analysis J. Am. Coll. Cardiol., October 1, 2001; 38(4): 991 - 998. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Giannitsis, M. Muller-Bardorff, S. Lehrke, U. Wiegand, R. Tolg, B. Weidtmann, F. Hartmann, G. Richardt, and H. A. Katus Admission Troponin T Level Predicts Clinical Outcomes, TIMI Flow, and Myocardial Tissue Perfusion After Primary Percutaneous Intervention for Acute ST-Segment Elevation Myocardial Infarction Circulation, August 7, 2001; 104(6): 630 - 635. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |